Finding the clinical utility of 1,5-anhydroglucitol among primary care practitioners.

ABSTRACT:

Background

HbA1c is widely used as the standard measure to track glycemic control in patients with diabetes and pre-diabetes but measures average levels of glycated hemoglobin over two to three months, with limited utility in the presence of recent and/or short-term fluctuations in glycemic control, which are correlated with worse patient outcomes.

Methods

We examined the clinical utility of 1-5-anhydroglucitol (1,5-AG) in six different, but common, case types of diabetes patients with short-term glycemic variability. We conducted a randomized controlled trial of simulated patients to examine the clinical practice patterns of primary care physicians before and after introducing 1,5-AG. The 145 participants were randomly assigned into standard care or standard care + 1,5-AG a

SUBMITTER: Peabody J 

PROVIDER: S-EPMC7184171 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature